Three patients with chronic lacticacidemia and deficiency of the pyruvate dehydrogenase complex demonstrated in cultured skin fibroblasts showed abnormalities on Western blotting with anti-pyruvate dehydrogenase complex antiserum which were not located in the E1 (alpha and beta) component of the complex. One of these patients had an enzymatically demonstrable deficiency in the E2 dihydrolipoyl transacetylase segment of the complex and very low observable E2 protein component on Western blotting of fibroblast proteins. The other two patients had abnormalities observable in the X component but no observable reduction in either E1, E2, or E3 enzymatic activities. One patient appeared to have a missing X component while the other had two distinct bands where X should be on Western blotting of fibroblast proteins. All three patients appeared to have severe clinical sequelae resulting from these defects. This is the first time that defects in either the E2 or the X component of the pyruvate dehydrogenase complex have been observed in the human population.
Introduction
The mammalian pyruvate dehydrogenase complex (PDHC)' differs from the complex in Escherichia coli and from the other mammalian a-keto-acid hydrogenases by the presence of a 53-kD protein that has been labeled protein X (1, 2) . This protein, whose mobility on sodium dodecyl sulfate polyacrylamide gels is slightly greater than the E3 component lipoamide dehydrogenase (Mr = 53,000), resembles the E2 dihydrolipoyl tranacetylase protein in that it bears a lipoyl group attached to a lysine residue (3, 4) . This lipoyl residue is capable of being acetylated when the complex is treated with pyruvate (1, 2) , though protein X itself has no innate dihydrolipoyl transacetylase activity. The study of human pyruvate dehydrogenase complex deficiency has shown that defects in the El compo-nent are most common, with a smaller number of E3 defects (5) . No case with defective E2 transacetylase activity has ever been described.
In the course of examining skin fibroblast cultures from patients with chronic lacticacidemia we have accumulated a group of cell lines from some 60 patients with either severe or partial deficiency of the pyruvate dehydrogenase complex (activities 0.5-60% of controls). We have reported recently in a review that in 51 patients we have the data to define the subcomponent of the complex responsible for the deficient activity by enzymatic analysis ofthe three catalytic components (6 normal; his height, weight, and head circumference have all been appropriate for age. Poor fine motor and gross motor coordination was evident at 5/2 yr of age. Blood lactate (2.5-9 mM) and pyruvate were above the normal range ofvalues on numerous occasions. At the age of 51/2 yr computed tomography (CT) scanning revealed bilateral basal ganglia lucencies and symmetrical lacunae in the area ofthe putamen. Blood alanine was elevated and urine organic acid analysis repeatedly showed the presence of leucine metabolites, 3-hydroxyisovaleric, 3-methylglutaconic, and 3-hydroxy-3-methylglutaric acids as well as moderate amounts of citric and a-ketoglutaric acid. Thiamine (25 mg daily) administration appeared to improve levels ofblood lactate while having no effect on clinical status.
Materials
Assay ofenzyme activities. Pyruvate dehydrogenase complex activity was measured in cultured skin fibroblasts before and after activation with 5 mM dichloracetate by the method of Sheu, Hu, and Utter (7).
The subcomponents of the complex were measured as follows: El by the method of Robinson, Taylor, and Sherwood (8), E2 by the method of Butterworth et al. (9) and E3 by the method of Reed and Wilms (10) modified as described in (8) .
Skinfibroblast cultures. Skin fibroblast cultures from patients with lacticacidemia were grown in a-MEM medium supplemented with 10% fetal calf serum. Cell lines with deficient pyruvate dehydrogenase complex activity were identified and assayed further for the components of the complex.
Western blotting. Western blotting was performed essentially by the procedure of Brada and Roth (11) except that peroxidase labeled final antibody was used for color development. Antibodies used were those raised in rabbits against bovine heart pyruvate dehydrogenase complex or pig heart lipoamide dehydrogenase (Sigma Chemical Co.).
Each lane for blotting was derived from two plates of confluent fibroblasts (2.6 X 106 cells) as follows. After removal of the culture medium the plates were extracted for 5 min with 1 ml 0.1% digitonin, 0.25 M sucrose, 1 mM EDTA, 20 mM MOPS (morpholinopropane sulphonate), pH 7.4. This digitonin extract was discarded and the cells were then extracted with 1% Triton X-100, 1 mm PMSF, 30 mM Hepes, 0.15 M NaCl, pH 7.4. This extract was subjected to acetone precipitation and after centrifugation the resulting protein pellet was solubilized by boiling in 1% SDS, 0.2 M DTT, 10% glycerol, 30 mM Tris HCI, pH 6.8, and loaded on to a 10% polyacrylamide slab gel. Transfer ofprotein was accomplished by electroblotting (Bio-Rad Laboratories, Richmond, CA) onto nitrocellulose support membranes.
These were blocked with 3% gelatin-TBS (20 mM Tris-HCl, 0.5 M NaCI, pH 7.5) for 1 h, followed by an overnight incubation with primary antibody (1:1,000). Incubation in secondary antibody (1:3,000) was for 3 h using goat anti-rabbit IgG horseradish peroxidase (Bio-Rad Laboratories).
Results
The three patients were found to have deficiency of the pyruvate dehydrogenase complex as judged by the activity in cultured skin fibroblasts (Table I) . Patients 1 and 2 had 23.7 and 12.3%, respectively, of the activities found in controls when assayed for PDH complex activity after activation by dichloroacetate. Patient 3, however, had 55% of control activity. Measurement of the activity was performed on two separately thawed fibroblast cultures and gave similar values. An independent assay by Dr. R. Butterworth (St. Luc Hospital, Montreal) gave an almost identical result (56% of control activity).
For comparison three cases of PDH complex deficiency in which the El component is deficient are included in Table I . Measurement of the subcomponents of the complex, the El decarboxylase, the E2 transacetylase and the E3 lipoamide dehydrogenase, showed that patients 2 and 3 had completely normal activity of all three components. Patient 1, however, had an E2 activity that was 32% of the control value. Thus the subcomponents of the PDH complex all appeared to be normal in patients 2 and 3, despite the decreased activity of the complex.
Western blotting of the proteins present in cultured skin fibroblasts was carried out using an antibody generated to pig heart pyruvate dehydrogenase complex. This antibody recognizes the components Ela, El,, E2, and X (Fig. 1 a) . Redeveloping with an antibody against pig heart lipoamide dehydrogenase revealed the E3 component (Fig. 1 b) . The The amount of X was also reduced in this patient. Patient 3, K.S. (Fig. 1, a and central nervous system damage seen in this patient in the basal ganglia would be atypical for this X-linked group who do not develop lesions in the central nervous system. The presence of one normal and one low relative molecular weight band for the X component suggests that one explanation for the high residual activity in the complex may be attributed to the normal appearing X. Some time ago the possibility that the X component of the PDH complex was a degradation product from E2 breakdown was shown to be unlikely because of the dissimilar appearance of tryptic digests of the two proteins (I, 2). However, the similarity in the construction and behavior of E2 and X still suggest a strong association between them. Matuda et al. have suggested that they are derived from differentially spliced transcripts of the same gene (13) . The appearance of patient 1 who lacks transacetylase activity and is deficient in E2 protein suggests some linkage because ofthe decreased protein X band seen by immunoblotting in this patient. On the other hand, patient 2 has a missing band for protein X but a reasonable band for the E2 protein. This could fit with the "one genetwo proteins" theory if the mutations had occurred at critical splice sites, but it would also be quite compatible with separate genes encoding the X and E2 proteins. Interestingly, the abnormality present in E2 affects measurable transacetylase activity but those in protein X do not. This suggests that X itself does not contribute significantly to the cellular dihydrolipoyl transacetylase activity despite the fact that the lipoyl groups on X can be acetylated (1, 2) . Ifthe PDH complex could be purified from patient derived cell lines in sufficient quantity to allow detailed study more information could be gained about the role ofthe two lipoyl proteins in the complex. The cloning and sequencing of X itself should be able to clarify much of the relationship between X and E2.
